Comparative Pharmacology
Head-to-head clinical analysis: ANZEMET versus ZOFRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZEMET versus ZOFRAN.
ANZEMET vs ZOFRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emesis.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
100 mg orally once daily, or 1.8 mg/kg (maximum 100 mg) intravenously over 15 minutes once daily.
8 mg orally or intravenously 30 minutes before chemotherapy; may repeat 8 mg orally 8 hours after first dose, then 8 mg orally every 12 hours for 1-2 days.
None Documented
None Documented
The terminal elimination half-life is approximately 5-7 hours in normal adults, but may be prolonged in patients with hepatic impairment (up to 11 hours) or severe renal impairment.
Terminal elimination half-life is approximately 3-4 hours in adults; in children (1 month to 12 years), half-life averages 2.5 hours; in elderly (≥75 years), half-life may be prolonged to 5.5 hours. Clinically, repeated dosing every 8 hours maintains antiemetic coverage.
Approximately 70% of the dose is excreted in urine (mostly as metabolites, with less than 10% as unchanged drug) and about 20% in feces via biliary elimination.
Approximately 5% of the dose is excreted unchanged in urine; the remainder undergoes extensive hepatic metabolism via CYP1A1, CYP1A2, CYP3A4, and flavin-containing monooxygenases, with metabolites excreted in urine (about 44-60% of total clearance) and feces (about 25-45%). Less than 10% is eliminated in bile.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)